①?gòu)娜蝿?wù)主手中獲取指定年報(bào)數(shù)量的年報(bào)文件（PDF） ②將年報(bào)中“合并利潤(rùn)”、“研發(fā)投入”、“分行業(yè)分產(chǎn)品分地區(qū)收入”、“治療領(lǐng)域”、“產(chǎn)銷量”、“研發(fā)投入明細(xì)”等數(shù)據(jù)填入相應(yīng)表格中（任務(wù)主提供填寫(xiě)模板） ③要求仔細(xì)認(rèn)真，有責(zé)任心。 ④價(jià)格2.5元/份年報(bào)預(yù)計(jì)40份，共計(jì)100元。 ⑤若審核發(fā)現(xiàn)有錯(cuò)填、漏填，以每漏填，錯(cuò)填一個(gè)數(shù)據(jù)1元計(jì)量扣除賞金 ⑥以前合作做過(guò)類似項(xiàng)目的優(yōu)先考慮，如有感興趣的威客可聯(lián)系參與。   [更多]

標(biāo)題： 1、The relationship between dose and antihypertensive effect for different AT1-receptor blockers 2、Kathryn F. Mills, Shohei Yoshida, Liana R. Stein7, et al.Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age- Associated Physiological Decline in Mice[J].Cell Metabolism. October 27, 2016. 3、Structure alerts for carcinogenicity and the Salmonella assay system: A novel insight through the chemical relational datebases technology. Mutation Res,2008,659(3):248-261. 4、Method development and validation of genotoxic impurities methyl methanesulfonate and methyl iodide in montelukast sodium drugsubstance by GC-MS. Kakasaheb, Nalavade Atul; Ramakrishna, K.; Srinivasarao, V..World Journal of Pharmaceutical Research (2014), 3(8), 557-567 5、ACS Combinatorial Science, 2014 , vol. 16, # 4 p. 168 - 175 6、 ACS Medicinal Chemistry Letters, 5(12), 1313-1317; 2014 7、Moisture transfer from stopper to product and resulting stability implications. 8、Product on Stopper” in a Lyophilized Drug Product: Cosmetic Defect or a Product Quality Concern? 9、Efficacy of oral tolvaptan versus 3% hypertonic saline for correction of?hyponatraemia?in post-operative patients. 10、Bioequivalence study of a valsartan tablet and a capsule formulation after single dosing in healthy volunteers using a replicated crossover design 要求：將符合標(biāo)題的文檔打包上傳   [更多]

1.需要以下四個(gè)省市醫(yī)保目錄：?? 湖南省? 天津?? 甘肅省?? 西藏自治區(qū) 2.要求不僅僅是文件，而是要把文件中的藥品目錄匯總到一張電子表格中，欄目樣式如同http://db.yaozh.com/yibao.html   [更多]

求購(gòu)一份FCC-14的PEPSIN ACTIVITY的檢測(cè)方法電子版原文   [更多]

① 從任務(wù)主手中獲取指定企業(yè)的年報(bào)文件， ② 將年報(bào)中的相應(yīng)數(shù)據(jù)填入相應(yīng)表格，年報(bào)中沒(méi)有的數(shù)據(jù)表格相應(yīng)內(nèi)容不做填寫(xiě)，（表格中要求的關(guān)鍵字段均為必填項(xiàng)） ③ 要求仔細(xì)認(rèn)真，熟悉英文或?qū)Ψg工具的熟練使用， ④ 需完成已有的72份年報(bào)數(shù)據(jù)提?。ㄌ顚?xiě)完了審核通過(guò)，每個(gè)年報(bào)要求把所有產(chǎn)品銷售額收集填寫(xiě)完）， ⑤ 如若審核發(fā)現(xiàn)有填錯(cuò)，填漏；以每填錯(cuò)，填漏一個(gè)數(shù)據(jù)1元計(jì)量扣除賞金。   [更多]

文獻(xiàn)名稱: 1.Sodium Diisopropylamide in Tetrahydrofuran: Selectivities, Rates, and Mechanisms of Arene Metalations 2.Advances toward LSD1 inhibitors for cancer therapy　 3.Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer 4.Practitioner Review: The effects of atypical antipsychotics and mood stabilisers in the treatment of depressive symptoms in paediatric bipolar disorder. 5.The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study. 6. G.A. Digenis, The in vivo behavior of multiparticulate versus single unit dose formulations, CAPSUGEL’s Symposium in Seoul, 1990. 7.Stability of salicylic acid and magnesium stearate by DSC 作者：L Macpherson ， S Sauerbrunn 出版源：《American Laboratory》 , 2006 , 38 (14) :16-20 備注 : 將符合要求的文獻(xiàn)PDF格式上傳   [更多]

100元獎(jiǎng)勵(lì)一條藥智網(wǎng)藥品轉(zhuǎn)讓信息數(shù)據(jù)庫(kù)沒(méi)有的信息 要求: 必須同時(shí)滿足以下幾條 1.藥智網(wǎng)藥品轉(zhuǎn)讓信息數(shù)據(jù)庫(kù)(網(wǎng)址:http://db.yaozh.com/index.php?action=zhuangrang)中沒(méi)有收錄的信息。 2.要轉(zhuǎn)讓的項(xiàng)目應(yīng)是正在轉(zhuǎn)讓的臨床批件或生產(chǎn)批件(包括藥廠或生產(chǎn)線轉(zhuǎn)讓),至少是取得了受理號(hào)的項(xiàng)目,還在臨床前研究的項(xiàng)目不符合要求. 3.以附件的形式將要轉(zhuǎn)讓的項(xiàng)目提交,一個(gè)公司的多個(gè)批文算一個(gè)項(xiàng)目 4.必須提供轉(zhuǎn)讓方的聯(lián)系方式,而不能是中介的聯(lián)系方式. 滿足以上幾點(diǎn)要求的,我們?cè)诖螂娫捄藢?shí)后,每個(gè)項(xiàng)目給予100元獎(jiǎng)勵(lì)   [更多]

左乙拉西坦口服溶液注冊(cè)標(biāo)準(zhǔn) 2006年標(biāo)準(zhǔn)（代）   [更多]

國(guó)內(nèi)上市藥品說(shuō)明書(shū)征集任務(wù) 現(xiàn)向廣大的同行征集藥品說(shuō)明書(shū)，共有2個(gè)任務(wù)，具體要求如下： 任務(wù)一：藥智網(wǎng)藥品說(shuō)明書(shū)數(shù)據(jù)庫(kù)（http://db.yaozh.com/instruct）中未收載品種 1.要求藥品說(shuō)明書(shū)是數(shù)據(jù)庫(kù)沒(méi)有收載的品種，數(shù)據(jù)庫(kù)里面查不到的品種（請(qǐng)先自行查詢）。 2.說(shuō)明書(shū)格式要求：圖片格式、PDF格式、WORD格式。無(wú)水印、無(wú)紅章、清晰，內(nèi)容完整、正確。 3.按照指定格式交稿。 4.一個(gè)合格的說(shuō)明書(shū)5元一個(gè)。 任務(wù)二：藥智網(wǎng)藥品說(shuō)明書(shū)數(shù)據(jù)庫(kù)（http://db.yaozh.com/instruct）中已收載品種 1.要求只有說(shuō)明書(shū)范本而未有具體生產(chǎn)企業(yè)的說(shuō)明書(shū)品種（請(qǐng)先自行查詢）。 2. 說(shuō)明書(shū)格式要求：圖片格式、PDF格式、WORD格式。無(wú)水印、無(wú)紅章、清晰，內(nèi)容完整、正確。 3.按照指定格式交稿 4. 一個(gè)合格的說(shuō)明書(shū)2元一個(gè)。 交稿方式：EXCEL表格目錄+文件 目錄的格式請(qǐng)見(jiàn)附件 之前在藥智匯發(fā)布的說(shuō)明書(shū)征集任務(wù)在此任務(wù)發(fā)布之日起截止，不再以之前的標(biāo)準(zhǔn)來(lái)征集。 有意向者可直接聯(lián)系我。 目錄的格式請(qǐng)見(jiàn)附件 之前在藥智匯發(fā)布的說(shuō)明書(shū)征集任務(wù)在此任務(wù)發(fā)布之日起截止，不再以之前的標(biāo)準(zhǔn)來(lái)征集。 有意向者可直接聯(lián)系我。   [更多]

標(biāo)題： 1、Perindopril-based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial 2、Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice: results from the STRONG prospective, observational, multicenter study 3、Bioequivalence study of two perindopril erbumine tablet formulations in healthy volunteers 4、Development and in vitro/in vivo evaluation of immediate release perindopril tablets 5、The advantages of combination therapy on hypertension: development of immediate release perindoprilindapamide tablet and assessment of bioequivalence studies 6、Does Chinese ethnicity affect the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors? - PubMed - NCBI 7、Drug Dev Ind Pharm. 2013 Jul;39(7):996-1004. doi: 10.3109/03639045.2012.689765. Epub 2012 May 25. A potent preparation method combining neutralization with microfluidization for rebamipide nanosuspensions and its in vivo evaluation. Shi Y1, Zou M, An Y, Ji Z, Gao P, Cheng G. 8、Drug Dev Ind Pharm. 2006 Jul;32(6):651-60. Production of an extremly low dose procaterol HCl preparation by fluidized-bed coating method: in vitro and in vivo evaluation. Yu TW1, Chen RR, Gau CS. 9、Enhancement of solubility and dissolution of cilostazol by solid dispersion technique. Park JH, Choi HK. Arch Pharm Res. 2015 Jul;38(7):1336-44. doi: 10.1007/s12272-014-0547-6. Epub 2015 Jan 8. 10、Solid-state amorphization of rebamipide and investigation on solubility and stability of the amorphous form. Xiong X, Xu K, Li S, Tang P, Xiao Y, Li H. Drug Dev Ind Pharm. 2017 Feb;43(2):283-292. doi: 10.1080/03639045.2016.1239627. Epub 2016 Oct 6. 要求：將符合要求的文獻(xiàn)PDF格式打包上傳   [更多]